MCP
AKTS icon

Mirador Capital Partners’s Aktis Oncology AKTS Stock Holding History

Mirador Capital Partners’s Portfolio AKTS Stock Details AKTS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$2.6M Buy
133,558
+93,434
+233% +$2.27M 0.3% 59
2026
Q2 		$1.29M Buy
+40,124
New +$824K 0.16% 93

Other funds holding AKTS

GWM
GK Wealth Management Reno, Nevada $178M AUM 41.48% 1-Year Est. Return
VCM
Versant Capital Management Phoenix, Arizona $1.17B AUM 28.44% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return
EP
Essential Partners Rancho Santa Fe, California $219M AUM 37.92% 1-Year Est. Return

Mirador Capital Partners's AKTS Position: Q3 2026 in Review

Mirador Capital Partners increased its Aktis Oncology (AKTS) stake by 233% in Q3 2026, buying an estimated $2.27M and bringing the position to 133,558 shares worth $2.6M. The position accounts for 0.3% of the portfolio, ranked #59.

Mirador Capital Partners first reported a position in AKTS in Q2 2026 and has held it in 2 quarters since. 6 funds tracked by Wall St. Rank hold AKTS as of Q3 2026.

  • Mirador Capital Partners held 133,558 shares of Aktis Oncology worth $2.6M as of Q3 2026.
  • Mirador Capital Partners bought 93,434 Aktis Oncology shares in Q3 2026, an estimated $2.27M.
  • Aktis Oncology made up 0.3% of Mirador Capital Partners's portfolio in Q3 2026, its #59 holding.
  • Mirador Capital Partners first reported a position in Aktis Oncology in Q2 2026 and has held it in 2 quarters since.
  • 6 funds tracked by Wall St. Rank held Aktis Oncology as of Q3 2026.

Based on Mirador Capital Partners's 13F filing for Q3 2026, filed 9 Oct 2026.